Table 3.
Baseline characteristics of the study population
| Patient number | Cancer type | Systemic tumor therapy within the last 3 months | Number of selected positive-uptake segments | TBRmean | ||
|---|---|---|---|---|---|---|
| |
|
|
FDG |
DOTATATE |
FDG |
DOTATATE |
| 1 |
Renal cell cancer |
None |
8 |
6 |
2.9 |
5.6 |
| 2 |
Follicular thyroid cancer |
TSH-suppressive therapy |
7 |
2 |
2.6 |
3.3 |
| 3 |
Pheochromocytoma, metabolically active (normetanephrines, dopamines) |
None |
3 |
4 |
2.1 |
3.9 |
| 4 |
Cancer of the gastric-esophageal junction |
Xeloda, single dose 2 days prior to FDG, 6 days prior to DOTATATE PET |
0 |
0 |
1.5 |
1.8 |
| 5 |
NET (stomach) |
None |
0 |
0 |
1.7 |
2.2 |
| 6 |
NET of unknown primary (liver metastases) |
None |
6 |
3 |
2.2 |
3.4 |
| 7 |
Carcinoid (rectum) |
One cycle of Lu-177-DOTATATE 8 weeks prior to FDG, 9 weeks to DOTATATE PET |
0 |
1 |
1.7 |
2.9 |
| 8 |
NET of unknown primary (liver metastases) |
None |
5 |
2 |
2.1 |
2.9 |
| 9 |
NET (pancreas) |
One cycle of cisplatin/etoposide 1 week after FDG; 4 weeks prior to DOTATATE PET) |
2 |
1 |
1.8 |
2.4 |
| 10 |
Carcinoid (lung), hormonally active |
None |
1 |
2 |
1.7 |
2.6 |
| 11 |
NET of unknown primary (liver metastases) |
Sandostatin LAR, last injection 4 weeks prior to DOTATATE PET, then stopped |
0 |
0 |
1.5 |
2 |
| 12 |
NET (ileum) |
None |
2 |
1 |
1.7 |
2.8 |
| 13 |
NSCLC |
None |
1 |
8 |
1.8 |
5.7 |
| 14 |
Papillary and follicular thyroid cancer |
TSH-suppressive therapy |
2 |
4 |
1.9 |
3.5 |
| 15 |
Follicular thyroid cancer |
TSH-suppressive therapy |
2 |
3 |
1.9 |
3.1 |
| 16 | Uterine cancer | None | 0 | 0 | 1.4 | 1.3 |
NET, neuroendocrine tumor; NSCLC, non-small cell lung cancer; TSH, thyroid-stimulating hormone.